These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26626581)

  • 1. Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.
    Xu H; Li J; Webber L; Kakkar R; Chen Y; Al-Huniti N
    J Clin Pharmacol; 2016 Aug; 56(8):999-1008. PubMed ID: 26626581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
    George JT; Kakkar R; Marshall J; Scott ML; Finkelman RD; Ho TW; Veldhuis J; Skorupskaite K; Anderson RA; McIntosh S; Webber L
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4313-4321. PubMed ID: 27459523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.
    de la Peña A; Ma X; Reddy S; Ovalle F; Bergenstal RM; Jackson JA
    J Diabetes Sci Technol; 2014 Jul; 8(4):821-9. PubMed ID: 24876428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men.
    Hu L; Jin Y; Li YG; Borel A
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):305-14. PubMed ID: 27136911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.
    Bi Y; Perry PJ; Ellerby M; Murry DJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):259-268. PubMed ID: 29436172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin.
    Han S; Kim YH; Choi HY; Kim MJ; Kim WJ; Park H; Bae KS; Lim HS
    Pharm Res; 2019 Aug; 36(10):146. PubMed ID: 31396727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men.
    Anderson RA; Cormier J; Thieroff-Ekerdt R; Boyce M; van den Berg F; Grau D; Turnquist D; Corzo D; Graham P
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4857-65. PubMed ID: 32946574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF; Huang JD
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
    Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
    Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.
    Schwahn M; Nagaraja NV; Derendorf H
    Pharm Res; 2000 Mar; 17(3):328-35. PubMed ID: 10801222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
    Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A
    Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
    An G; Liu W; Duan WR; Nothaft W; Awni W; Dutta S
    AAPS J; 2015 Mar; 17(2):416-26. PubMed ID: 25567367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.